These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 31226985)

  • 1. Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.
    Papp KA; Gooderham M; Beecker J; Lynde CW; Delorme I; Dei-Cas I; Albrecht L; Rampakakis E; Sampalis JS; Vieira A; Hussein S; Chambenoit O; Rihakova L
    BMC Dermatol; 2019 Jun; 19(1):9. PubMed ID: 31226985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
    Papp KA; Gooderham M; Lynde C; Brassard D; Al-Mohammedi F; Prajapati VH; Delorme I; Albrecht L; Haydey R; Alam MS; Beecker J; Siddha S; Maguin M; Farag MS; Vieira A; Rihakova L; Langley RG
    Arch Dermatol Res; 2024 Jun; 316(7):362. PubMed ID: 38850346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data.
    Papp KA; Gooderham M; Dei-Cas I; LopezTello A; Garcia-Rodriguez JC; Taveras CY; Rousselin AH; Lavieri A; Maiolino M; Quintero DGV; Rihakova L; Salibe M; Pertuz W
    Dermatol Ther (Heidelb); 2023 Jan; 13(1):269-283. PubMed ID: 36496547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
    Wong IT; Shojania K; Dutz J; Tsao NW
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis.
    Phung M; Ighani A; Georgakopoulos JR; Vender R; Giroux L; Lansang P; Yeung J
    J Cutan Med Surg; 2019; 23(4):391-393. PubMed ID: 30991818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
    Ortiz-Salvador JM; Saneleuterio-Temporal M; Magdaleno-Tapial J; Velasco-Pastor M; Pujol-Marco C; Sahuquillo-Torralba A; Mateu-Puchades A; Pitarch-Bort G; Marí-Ruiz JI; Mataix-Díaz J; Montesinos-Villaescusa E; Miralles-Botella J; García-Fernández L; Martorell-Calatayud A; Belinchón-Romero I; Sánchez-Carazo JL; Pérez-Ferriols A
    J Am Acad Dermatol; 2019 Aug; 81(2):427-432. PubMed ID: 30872150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.
    Körber A; Thaçi D; von Kiedrowski R; Bachhuber T; Melzer N; Kasparek T; Kraehn-Senftleben G; Amon U; Augustin M
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):411-419. PubMed ID: 28960469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry.
    Strober BE; Germino R; Guana A; Greenberg JD; Litman HJ; Guo N; Lebwohl M
    J Dermatolog Treat; 2020 Jun; 31(4):333-341. PubMed ID: 31035822
    [No Abstract]   [Full Text] [Related]  

  • 11. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
    Blauvelt A; Prinz JC; Gottlieb AB; Kingo K; Sofen H; Ruer-Mulard M; Singh V; Pathan R; Papavassilis C; Cooper S;
    Br J Dermatol; 2015 Feb; 172(2):484-93. PubMed ID: 25132411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.
    Lebwohl MG; Blauvelt A; Menter A; Papp KA; Guenthner S; Pillai R; Israel RJ; Jacobson A
    Am J Clin Dermatol; 2019 Dec; 20(6):863-871. PubMed ID: 31493163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study.
    Ding Y; Li W; Guan X; Liu N; Zhou Y; Li G; Wang X; Wang Z; Xiao X; Yang B; Lv C; Zhang C; Shi Y
    Clin Transl Sci; 2023 Oct; 16(10):1803-1814. PubMed ID: 37644777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
    Paul C; Lacour JP; Tedremets L; Kreutzer K; Jazayeri S; Adams S; Guindon C; You R; Papavassilis C;
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study.
    Okubo Y; Ohtsuki M; Morita A; Yamaguchi M; Shima T; Tani Y; Nakagawa H;
    J Dermatol; 2019 Mar; 46(3):186-192. PubMed ID: 30672623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry.
    Bonomo L; Abittan BJ; Hashim PW; Karki C; Mason M; Lebwohl M
    J Drugs Dermatol; 2019 Aug; 18(8):731-740. PubMed ID: 31424705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors.
    García-Martín E; Romero-Jiménez RM; Baniandrés-Rodríguez O; Escudero-Vilaplana V; Benedí-González J; de Los Ríos Luna PM; Herranz-Alonso A; Sanjurjo-Sáez M
    Eur J Hosp Pharm; 2024 Aug; 31(5):409-415. PubMed ID: 37094886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents.
    Ighani A; Partridge ACR; Shear NH; Lynde C; Gulliver WP; Sibbald C; Fleming P
    J Cutan Med Surg; 2019; 23(2):204-221. PubMed ID: 30463416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
    Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
    J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.